New Capability Enables Individuals Identified as High-Risk by Participating Health Plans to Access Screening through a Quest Diagnostics Site
Builds on Quest’s Extended Care Services to Improve Care Quality and Outcomes in Diabetes and Other Chronic Diseases
SECAUCUS, N.J., April 4, 2022 /PRNewswire/ — Quest Diagnostics (NYSE:DGX), the world’s leading provider of diagnostic information services, today announced a collaboration with IRIS (Intelligent Retinal Imaging Systems) to deliver diabetic retinal imaging services through designated Quest Diagnostics patient service centers across the United States to aid in screening patients for retinal assessment by a healthcare provider. The collaboration aims to increase convenience and improve screening rates for diabetic retinopathy, the leading cause of blindness in the United Statesi, for members of population health management programs sponsored by health plans.
